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Cryptogenic Stroke and Migraine 
Headache: The Clinical Cardiologist’s 
View
Harold L. Kennedy, MD
A B S T R A C T
Cryptogenic stroke and migraine headache are disorders which most commonly af-
fect persons younger than 55 years of age. In recent years these disorders have been 
found to have a strong association with inter-atrial cardiac defects, such as patent fo-
ramen ovale and atrial septal defect, and support the pathophysiological mechanism 
of paradoxical embolism with a right-to-left shunt. With the evolution of technol-
ogy, magnetic resonance imaging has more clearly defined cryptogenic stroke, and 
percutaneous cardiac interventional devices have offered a simplified approach to 
closure of inter-atrial cardiac defects. Nevertheless, the evidence-based data of which 
sub-populations of patients with cryptogenic stroke or migraine headache will benefit 
from closure of inter-atrial cardiac defects is just being defined. This review offers a 
clinical cardiologist’s viewpoint of these developments.
C R Y P T O G E N I C  S T R O K E
T H E  C L I N I C A L  P R O B L E M
Stroke is a leading cause of death and long-term disability worldwide. Eighty-five 
percent of strokes are ischemic, and most ischemic strokes occur in persons older 
than 65 years of age in tandem with the development of atherosclerosis. Although a 
minority of ischemic strokes in the community affect younger adults, as many as half 
the patients referred to tertiary care centers are younger than 65 years of age, and up 
to 12% are younger than 45 years [1]. Young patients with ischemic stroke often have 
few, if any, risk factors for atherosclerosis. Initial evaluation of the cerebral arteries 
is essential but frequently unrevealing, and thus in many cases the focus must shift to 
the detection of potential cardiac sources of embolism that are commonly associated 
with, and that may cause, unexplained stroke in young persons [2].
In as many as 43% of affected young adults, strokes are cryptogenic (i.e., they do 
not have a definite cause despite extensive evaluation) [1]. This brain infarction which 
is commonly revealed by a magnetic resonance imaging (MRI) abnormality without 
an etiology is the essence of a cryptogenic stroke. The most prevalent potential source 
of cardioembolism in young adults (<55 years) with cryptogenic stroke is a patent 
foramen ovale (PFO), which is detected in more than half of such persons undergoing 
evaluation [3]. On the other hand, cryptogenic strokes in the middle-aged and elderly 
(>55 years) patients account for approximately one-third of ischemic strokes, and have 
most commonly been associated with aortic arch atheromatous plaques [4,5]. Trans-
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esophageal echocardiographic (TEE) detection of plaques 
4 mm proximal to the ostium of the left subclavian artery 
in the elderly have been found to be significant predictors of 
new brain infarcts and other vascular events [4,5].
This presentation focuses on the majority of brain infarc-
tions which occur in the young and have been found to be 
associated with interatrial septal abnormalities [PFO, atrial 
septal defect (ASD) or atrial septal aneurysm (ASA)], cardiac 
valvulopathies, dissections of extracranial arteries or hyper-
coagulable states [6]. Whereas the latter conditions render a 
definable etiology of stroke, there remains in approximately 
50 to 60% of patients younger than 55 years of age (despite a 
thorough evaluation) an unknown cause. In these cryptogenic 
stroke patients, the presence of a PFO or ASD has been found 
by TEE in approximately 40 to 50% of patients, and strongly 
suggests that the pathologic mechanism of disease is paradoxi-
cal embolism [6,7].
PA T E N T  F O R A M E N  O VA L E  A N D  C R Y P T O G E N I C  
S T R O K E
A PFO has been defined by autopsy series to occur in 25 
to 27% of the population, and is large (0.6 to 2.0 cm) in 6% 
[7,8]. PFO frequency and size have been found to vary by age 
and size, and may be an important factor in acting as a conduit 
in paradoxical embolism [7,8]. Cryptogenic stroke patients 
appear to have larger PFOs than that of control patients [8].
In the recent PFO in Cryptogenic Stroke Study (PICSS), it 
has also been shown that large PFOs were significantly more 
prevalent among cryptogenic stroke patients compared with 
those with known cause of stroke [9]. Additionally, stroke 
patients with larger PFOs have brain imaging findings sug-
gestive of an embolic mechanism 10 and PFO size may be an 
independent risk factor for recurrent cerebrovascular events 
[8].
O T H E R  FA C T O R S  R E L A T E D  T O  P F O  
A N D  C R Y P T O G E N I C  S T R O K E
The prevalence of atrial septal aneurysm (ASA) is greater 
among patients with embolic events. It is also well known that 
ASA is associated with PFO, with 60% of patients with ASA 
having a PFO [11]. Additionally, the PFOs seen in the presence 
of ASA tend to be large compared with those seen without 
associated ASA [12]. Thus, the association of ASA with em-
bolic events is likely based on the high prevalence of large 
PFOs. Because an ASA is usually highly mobile, protruding 
from right to left atrium, it is unlikely that a thrombus forms 
in situ in the ASA itself.
The eustachian valve is a membrane-like structure in the 
right atrium. Among adults, a eustachian valve can cause a 
significant right-to-left shunt in the presence of a PFO or ASD 
by directing the blood flow pattern to the interatrial defect 
[13]. These prominent eustachian valves have been found more 
commonly in patients with presumed paradoxical embolism 
than in control patients [13]. The presence of Chiari’s network 
and filamentous strands which occur in the right atrium in 
some patients, have also been defined to have an association 
with PFO [14].
The hemodynamics which favor right-to-left shunting 
through an interatrial communication, also play a role in 
determining the probability of paradoxical embolization 
in patients with cryptogenic stroke. Whereas aging with its 
changes in right atrial pressure is an infrequent confounding 
factor not found to be significantly associated with cryptogenic 
strokes, the patient who presents with pulmonary embolus, 
right ventricular infarction or severe tricuspid regurgitation 
will have an elevated right-to-left shunt through a PFO [7].
More recently, pelvic vein thrombi have been reported 
to be found in young cryptogenic stroke patients compared 
to those with known causes of stroke [15]. Since these veins 
are rarely studied in such patients, their consideration as a 
contributing factor must also be borne in mind. Patients 
with a hypercoaguable state have also been defined within 
the cohorts of cryptogenic stroke [16]. The higher frequency 
of prothrombotic states associated with G20210A and factor 
V Leiden mutations in patients with cyrptogenic stroke and 
PFO suggests a contributory mechanism to the suspected 
paradoxical embolization [16].
R E C U R R E N T  S T R O K E  P R E V E N T I O N  
A N D  T R E A T M E N T
The focus of medical treatment for cryptogenic stroke 
is to prevent recurrent events. Such therapy has employed 
antithrombotic (warfarin and antiplatelet) regimens, and 
surgical and device closures of PFO or ASD. Whereas a 
summary of medical therapy studies following cryptogenic 
stroke patients (N=943) for a mean duration of 33 months 
found the annual rate of recurrent stroke to be 1.98% and 
stroke or death at 3.12%, these studies are confounded by 
different age groups [7]. In a retrospective analysis from the 
PFO in Cryptogenic Stroke Study (PICSS), the presence of a 
PFO in younger cryptogenic stroke patients did not seem to 
increase the risk of adverse events, but significantly increased 
events in older patients [17]. Thus, age is an important con-
founding factor. Only one study has randomized patients to 
warfarin or aspirin therapy, and found no difference in event 
rates [9]. There exists no randomized controlled prospective 
trials examining the effects of aspirin and/or clopidogrel 
versus warfarin in cryptogenic stroke patients, and although 
such therapy is commonly employed, definitive data do not 
exist. Because of the known major bleeding risk of warfarin 
at 1 to 2% annually, and minor bleeding risk of 10 to 20%, 
empiric therapy today has commonly employed aspirin and 
clopidogrel strategies [7].
Surgical closure studies of PFO and ASD in the literature 
have examined less that 200 patients and have defined the an-
nual rate of recurrent stroke as <0.34% and stroke or death 
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<1.0% [7]. Nevertheless, the development of percutaneous 
closure devices have seemingly obviated the need for surgery 
with its attendant morbidity and cost, even considering mini-
mally invasive techniques [18]. Thus, attention has focused 
on the use of transcatheter closure devices (e.g Amplatzer, 
CardioSeal and StarFlex devices) to occlude the interatrial 
communication of PFO and ASDs. These devices in over 1400 
patients followed showed an annual rate of recurrent stroke of 
0.19% and stroke or death of 1.15% [7]. Complications from 
such devices include major events such as death, hemorrhage, 
cardiac tamponade and fatal pulmonary emboli, and are esti-
mated to occur in 1.5% of patients [7]. It is intuitive that this 
latter figure is highly dependent on the emergence of varied 
new and sub-optimal devices, as well as lack of experience in 
some operators. Minor complications of atrial arrhythmias, 
device embolization, device thrombosis, ECG changes, and 
arteriovenous fistula formation are reported in 7.9% [19].
There are 3 ongoing randomized studies in the United 
States comparing the efficacy of percutaneous closure with 
medical therapy in cryptogenic stroke patients. The Ran-
domized Evaluation of Recurrent Stroke Comparing PFO 
Closure to Established Current Standard of Care Treatment 
(RESPECT) trial randomizes cryptogenic stroke patients 
with PFO to percutaneous closure with an Amplatzer device 
or medical therapy (antiplatelet or warfarin at the enrolling 
physician’s discretion). The CLOSURE I trial randomizes 
patients with stroke or transient ischemic attack (TIA) thought 
to be due to paradoxical embolization to percutaneous closure 
with the STARFlex septal occluder or medical therapy (aspirin 
and/or warfarin at the enrolling physician’s discretion). The 
Cardia PFO trial randomizes patients to PFO closure using its 
PFO closure device or warfarin. The Amplatzer device is also 
used in Europe and Australia in the Patent Foramen Ovale 
and Cryptogenic Embolism PC-trial. This study randomizes 
cryptogenic stroke patients with PFO to device closure or 
medical therapy (antiplatelet or warfarin at the enrolling 
physician’s discretion). Finally, the CLOSEUP (Closure Us-
ing Premere) trial will be using a new PFO closure device 
(Premere) and similarly randomize patients to percutaneous 
device closure or medical therapy. Of note, in all trials, patients 
randomized to the device arm also receive medical therapy for 
a variable period of time, in some cases for the study duration. 
These studies seek to demonstrate the superiority of device 
plus medical therapy over medical therapy alone.
T H E  C L I N I C I A N ’ S  V I E W
Cryptogenic stroke (i.e. without apparent cause or source) 
is predominantly a disorder of middle-aged and younger per-
sons (<55 years). When it occurs in older individuals (>55 
years) a search for aortic arch atheroma and arteriosclerotic 
disease is indicated. But the vast majority of such strokes occur 
in younger individuals, where the most prevalent suspected 
etiology is the mechanism of paradoxical embolism through 
an interatrial abnormality (PFO or ASD). Investigation by 
transcranial Doppler or TEE with saline venous infusion 
(bubble study) are the diagnostic methods of choice to lead 
the investigation. Definition of the atrial anatomy and other 
factors contribute to the probability of the suspected paradoxi-
cal embolism. Treatment with modern anti-thrombotic therapy 
(i.e. aspirin and clopidogrel) currently seems warranted as a 
first-line of defense to prevent recurrent stroke, particularly in 
view of the long-term cost and morbidity of warfarin therapy 
in this predominantly young patient group. Subsequently, sec-
ond-line referral of patients with large PFOs, and identified 
atrial abnormalities (i.e. large defects, prominent Eustachian 
valve or Chiari network or filamentous strands or ASA) for 
transcatheter closure to an experienced center seems indicated 
according to the results of non-randomized studies and by 
expert consensus. Lastly, referral for participation in prospec-
tive randomized clinical trials employing both medical therapy 
and closure devices should be supported for those individuals 
whose clinical features do not predominantly argue for the 
mechanism of paradoxical embolization to help define the 
best treatment to prevent recurrent stroke.
M I G R A I N E  H E A D A C H E
T H E  C L I N I C A L  P R O B L E M
Migraine is a common disorder, with a one-year prevalence 
rate in Americans of approximately 13% (18% of women and 
6 to 7% of men) [20]. Migraine is thus about three times more 
common in women than men. It tends to run in families, and 
typically it is a disorder of young, primarily healthy women. 
Migraine without aura is the most common type, accounting 
for approximately 80% of all migraine sufferers. Nonpharma-
cologic modalities, such as regular exercise, relaxation, stress 
management, biofeedback, ice massage, physical therapy tech-
niques, and others may play an important role in both the 
prophylactic and abortive treatment of migraine, although the 
data are somewhat limited [21]. Migraine is thought to have 
a polygenetic and multifactorial etiology [22]. No consistent 
genetic basis has been established for migraine, with the ex-
ception of familial hemiplegic migraine.
T H E  PA T H O P H Y S I O L O G Y
No single theory or hypothesis can explain all of the phe-
nomena that occur with migraine. The once popular vascular 
theory of migraine, which suggested that vascular headaches 
such as migraine and cluster headaches were caused by the 
dilatation of blood vessels, while the aura of migraine resulted 
from vasoconstriction, is no longer considered viable in its 
original form. Nevertheless, it may well be that vasodilatation 
plays an important role in the severe throbbing head pain that 
is characteristic of migraine; vasodilatation itself is probably 
an epiphenomenon, resulting from instability in the central 
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neurovascular control mechanism. 23
The current state of knowledge in this field suggests that a 
primary neuronal dysfunction leads to a sequence of changes 
intracranially and extracranially that account for migraine, 
including the three phases of prodrome, aura, and headache 
[24]. Individuals prone to migraine have a genetic migrainous 
threshold that renders them susceptible to an acute migraine 
attack depending upon the balance between excitation and 
inhibition at various levels of the nervous system. Both genetic 
and environmental factors are important [25].
Serotonin (released from brainstem serotonergic nuclei) 
also plays an important role in the pathogenesis of migraine; 
this is probably mediated via its direct action upon the cranial 
vasculature, through its role in central pain control pathways 
and through cerebral cortical projections of brainstem sero-
tonergic nuclei [26]. The exact mechanism of serotonin action 
remains obscure. A decline in serotonergic function has been 
noted during acute migraine attacks, resulting in vasodilation 
of cranial vessels and sensitization of meningeal afferents of 
the trigeminal nerve [27]. Between attacks, patients who 
have migraine without aura appear to have increased brain 
serotonin synthesis [28].
More recently, migraine with aura has been linked to 
right-to-left cardiac shunts, usually in the setting of a patent 
foramen ovale (PFO) or, much less often, an atrial septal 
defect (ASD) [29,30]. In a study of 581 cryptogenic stroke 
patients, migraine was more common in the 46% of patients 
with PFO than those without PFO (27% versus 14%) [30]. 
In other reports, patients with migraine associated with aura 
were more likely to have a PFO than patients with migraine 
without aura or controls [31,32].
The mechanism of the association between right-to-left 
cardiac shunt and migraine is not known. One theory is that 
the venous circulation contains vasoactive substances (e.g. 
serotonin) capable of triggering migraine; these are normally 
inactivated in the lungs but gain access to the cranial circula-
tion in the presence of a right-to-left shunt [24]. However, a 
recently favored hypothesis is that the existence of a right to 
left shunt provides a pathway for paradoxical embolism of 
microemboli (1 to 3 mm) and subsequent cerebral ischemia, 
which in turn triggers migraine. This hypothesis is aided by 
a recent study which demonstrated a 13.7-fold higher inci-
dence of MRI lesions in migraine patients with aura than in 
controls [34].
Moreover, recent clinical studies of cryptogenic stroke 
patients with migraine, strongly attest to the benefit of PFO 
or ASD closure in the resolution or improvement of symptoms 
in migraine patients [30,32,33] Migraine headache has been 
defined in 35 to 42% of cryptogenic stroke patients, with as 
many as two-thirds of those patients experiencing migraine 
with aura [30,33]. Complete resolution of migraine symptoms 
following closure of the PFO or ASD in patients with migraine 
and aura has been found to occur in 56 to 75% of such patients 
[30,33]. The association of migraine and PFO is even stronger 
in patients with PFO and atrial septal aneurysm [29].
In the recently reported Migraine Intervention with 
Starflex Technology (MIST) trial, 35 patients, aged 18 to 
60 years, with a one-year documented history of migraine 
with aura occurring at least 5 times per month were studied. 
Additional selection criteria of failed medication from two 
classes of prophylactic medications and at least 7 days free 
of headache per month were required. Screening of 432 pa-
tients resulted in identifying 147 patients, 84% women, mean 
age 44 years, who were randomized to PFO closure with the 
STARFlex Septal Repair Implant (n=74) or a sham proce-
dure (control group; n=73). Patients but not physicians were 
blinded to randomized treatment. Patients were followed for 
6 months regarding migraine frequency and severity, during 
which patients were treated with aspirin and clopidogrel for 
the first 3 months. Exclusions from the trial included migraine 
medication overuse, prior stroke/TIA and cardiac anomaly 
FIGURE 1. Percutaneous Closure of a Patent Foramen Ovale. 
With use of a femoral approach, a transvenous sheath is ad-
vanced across the foramen into the left atrium, where a folded 
disk is expanded and pulled back, apposing the primum and 
secundum septa closed. This step is followed by deployment of 
a right-sided disk, at which time the two-disk device is released. 
Clopidogrel and aspirin are recommended for a period of three 
months to prevent thrombus formation on the device, with as-
pirin therapy continued for an additional three months, when 
endothelialization is complete. Antibiotic prophylaxis for six 
months is recommended. Complete late closure of the foramen 
has been reported in 80 to 95% of patients. (Reproduced with 
permission from N Engl J Med 2005; 353:2368 [6]).
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contraindications.
The principal findings showed among the 432 patients 
screened in the trial, 60.2% had an atrial right-to-left shunt, 
much higher than typically found in the general population 
(i.e. 27%). A large atrial shunt was present in 37.7% of pa-
tients, with a small shunt in 16.7% and no shunt in 39.8% [35]. 
The mean diameter of PFO in the trial was 9.21 mm. There 
was no difference between groups in the primary endpoint 
of complete cessation of migraines, with 3 patients in each 
group meeting this criterion. Reduction in headache-days by 
at least 50% occurred more frequently in the PFO closure 
group (42% vs 23%, p=0.038). The reduction in headache 
burden, defined as the frequency x duration of headache, 
was greater (37% vs 14%) in the PFO closure group (from 
136.1 at baseline to 86.06 at follow-up, p=0.033 in PFO 
group; from 116.8 at baseline to 96.32 at follow-up, p=NS 
in control group). Thus among migraine sufferers screened 
for enrollment in the trial, PFO closure was not associated 
with a difference in total migraine resolution compared with 
a sham procedure. While the primary endpoint did not differ 
by treatment group, reduction of headache frequency by 50% 
occurred more frequently in the PFO group. This endpoint 
is not as rigid as the total elimination endpoint but would be 
clinically important to patients experiencing migraines. The 
on-going MIST II trial will evaluate PFO closure for migraine 
improvement but will incorporate a longer patient follow-up, 
with the hypothesis that much of the benefit may emerge later 
following PFO closure.
T H E  C L I N I C I A N ’ S  V I E W
Whereas the medical therapy of migraine is beyond the 
scope of this presentation, in the patient with migraine, the 
possibility of a PFO or ASD with paradoxical embolism must 
be strongly considered as a pathologic mechanism. This is 
particularly true when the migraine is accompanied by an 
aura. Diagnostic studies should include a transcranial Dop-
pler study with venous saline injection (bubble study), or a 
transesophageal echocardiogram with venous saline injection 
(preferably from the femoral vein whose flow is directed into 
the area of potential PFO). Definition of other risk factors 
associated with paradoxical embolism (e.g a gradient favor-
ing right to left shunt, presence of Eustachian valve or Chiari 
strands) should heighten one’s suspicion that closure of an 
interatrial communication could render substantial benefit in 
alleviating the occurrence of migraine, and lead to a resolution 
or marked decrease in symptoms.
Currently, definitive evidence from prospective random-
ized clinical trials establishing the benefit of PFO or ASD 
closure for migraine headache is still lacking. The prelimi-
nary results of the first such randomized trial (MIST) were 
just presented at the ACC Meeting (March 2006) [35]. The 
MIST trial studied 147 patients with migraine and a PFO who 
were randomly assigned to sham treatment (n=73) or PFO 
closure (n=74). At 6 months 50% reduction in headache-days 
frequency was achieved by 42% of patients who had the PFO 
closed versus 23% in the sham arm. However, the primary 
end-point, complete elimination of headache, was achieved 
by only 3 patients in each group. More randomized trials, such 
as the MIST-II, ESCAPE (Effect of Septal Closure of Atrial 
PFO on Events of Migraine with Premere), FORMAT (Patent 
Foramen Ovale Closure to Reduce Migraine Attacks), and 
the PREMIUM trial (Prospective Randomized Investigation 
to Evaluate Incidence of Headache Reduction In Subjects 
with Migraine & PFO Using the Amplatzer PFO Occluder 
Compared to Medical Management) are currently in progress, 
which are anticipated to render further knowledge about the 
benefit of percutaneous PFO closure on the occurrence and 
severity of migraine headaches.
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